Part,  Chapter, Paragraph

  1    I,     2.  4       |        give volume movements only, i.e. price movements will not
  2    I,     2.  5       |        from the new member states (i.e. Eastern European countries).
  3    I,     2.  6       |          tertiary level education (i.e. ISCED levels 5 or 6) in
  4    I,     2.  6       |   enrolling in ISCED 6 programmes (i.e. those graduating are those
  5    I,     2. 10.  4   |           a truly internal market, i.e. one of the primary objectives
  6    I,     3.  1       |          also a demographic factor i.e. the rise in the mean age
  7    I,     3.  1       |             who turned 50 in 2005 (i.e. they are currently at the
  8    I,     3.  1.  0(1)|     understood in a macro context, i.e. the relative change that
  9    I,     3.  1       |           discovering a pregnancy, i.e. the conception rates outside
 10    I,     3.  2       |         natural population growth (i.e. the number of births minus
 11    I,     3.  2       |           diminished to 7 percent, i.e. it nearly halved during
 12    I,     3.  2       |      natural growth at the moment (i.e. a higher number of deaths
 13    I,     3.  2       | accommodate 23 million immigrants, i.e. over 7% of their population.
 14    I,     3.  2       |         total population is large (i.e. 37%). According to GCIM (
 15    I,     3.  3       |            with the age structure, i.e. the number of individuals
 16   II,     4.  1       |      quantity and quality of life (i.e. between total longevity
 17   II,     4.  2       |      Central and Eastern European (i.e. Bulgaria, the Czech Republic,
 18   II,     5.  1.  1   |            causes of this disease, i.e., hepatitis B and C virus (
 19   II,     5.  1.  2   |           and close relationships, i.e. all the things we probably
 20   II,     5.  1.  3   |          various characteristicsi.e. personal, family, professional,
 21   II,     5.  1.  4   |            know what good care is, i.e. he/she must be informed
 22   II,     5.  3.  1   |           to the cancer diagnosis (i.e. 1-year, 3-years, 5-years
 23   II,     5.  3.  3   |         cancer outcome indicators (i.e. incidence, mortality, survival)
 24   II,     5.  3.  6   |          countries in macro-areas (i.e. Northern, Western, Southern
 25   II,     5.  3.  6   |        Eastern European countries, i.e those with the lowest level
 26   II,     5.  3.  8   |            prevalent cancer cases (i.e. increased needs of the elderly
 27   II,     5.  3.  8   |         over the next 10-20 years (i.e.: European implementation
 28   II,     5.  4.  2   |        registers are client-based, i.e. they use only a portion
 29   II,     5.  4.  2   |     available in the first report (i.e. lower extremity amputations
 30   II,     5.  4.  4   |        risk factor for prevention, i.e. body mass index, increases
 31   II,     5.  4.  4   |          from scientific evidence, i.e. the measuring of one’s waist
 32   II,     5.  4.  6   |         requirements of relevance (i.e they should provide relevant
 33   II,     5.  5.  3   |            The highest risk group (i.e., 2024-year-old females)
 34   II,     5.  5.  3   |      admissions due to ICD-10/F20, i.e. the chapter including schizophrenia,
 35   II,     5.  5.  3   |           portion is even higheri.e. more than two fifths. According
 36   II,     5.  5.  3   |     stronger tendency to be obese, i.e. a 1.5 to 4 times increased
 37   II,     5.  5.  3   |     billion (Euros 36.2 billion) – i.e. over eight times as much.
 38   II,     5.  5.  3   |           degree of ascertainment, i.e. for the use of registry
 39   II,     5.  5.  3   |  distribution, biological factors, i.e., differences in environmental
 40   II,     5.  5.  3   |         year 2005 was €13 billion, i.e., €27 per European inhabitant.
 41   II,     5.  5.  3   |           are available in Europe, i.e., beta-interferons 1a and
 42   II,     5.  5.  3   |      sample of European countries (i.e. number of unemployed people
 43   II,     5.  5.  3   |           of the patient’s status (i.e. the strengthening of MS
 44   II,     5.  5.  3   |       studies on the economics of (i.e. the cost of illness of)
 45   II,     5.  6.  3   |            falling, low bone mass, i.e. osteoporosis, and previous
 46   II,     5.  6.  3   |            that is comprehensible, i.e. 5 to 10 years (Kanis et
 47   II,     5.  7.  1   |        stage renal disease (ESRD), i.e. the disease stage where
 48   II,     5.  7.  1   |           spent for ESRD patients, i.e. 0.083% of the general population (
 49   II,     5.  7.  3   |     Prevalence of stages 3-5 CKD - i.e. the stages showing a higher
 50   II,     5.  7.  5   |            cardiovascular disease (i.e. those individuals in whom
 51   II,     5.  7.  5   |          The registry of patients (i.e. The Statistical Yearbook
 52   II,     5.  7.  6   |           www.healthypeople.gov/), i.e. a document that challenges
 53   II,     5.  8.  5   |   population at high risk of COPD, i.e. smokers, can reveal the
 54   II,     5. 10.  2   |         gold standard methodology (i.e food challenge studies and
 55   II,     5. 11.  3   |           the examining physician (i.e. required only a moisturizer),
 56   II,     5. 12.  1   |            causes of this disease, i.e., hepatitis B and C virus (
 57   II,     5. 12.  2   |          change in rate over time (i.e., no joinpoint, which is
 58   II,     5. 12.  3   |       Southern and Central Europe, i.e. Portugal (38.7/100,000),
 59   II,     5. 12.  4   |            causes of this disease, i.e., hepatitis B and C virus (
 60   II,     5. 12.  6   |        very advanced and selected (i.e. comparatively younger) cases,
 61   II,     5. 13       |          needs) energy-dense food (i.e. food containing large amounts
 62   II,     5. 14.  2   |          type de services provided i.e. the number of teeth extracted
 63   II,     5. 14.  2   |    fillings, but not the outcomes, i.e. whether interventions contributed
 64   II,     5. 14.  2   |   synthesis international articles i.e. Pubmed databases are the
 65   II,     5. 14.  3   |     collected that dental erosion, i.e. the loss of tooth enamel
 66   II,     5. 14.  5   |          to specific life-stylesi.e. children or elderly people;
 67   II,     5. 15.  3   |            established clinically, i.e. by expert clinicians. The
 68   II,     6.  3.  1   |          costs and indirect costs (i.e. the impact on sectors other
 69   II,     6.  3.  2   |        broad-spectrum antibiotics, i.e. antibiotics that kill a
 70   II,     6.  3.  3   |         continued throughout 2005, i.e. a rise in diagnoses in men
 71   II,     6.  3.  6   |          standardised information, i.e. returning travellers used
 72   II,     7.  2.  3   |           level of desegregations, i.e. CARE comprises detailed
 73   II,     7.  3.  2   |            combine all age groups, i.e. young through to old together,
 74   II,     7.  4.  5   |          and/or consumer services (i.e. tourism services, sports
 75   II,     8.  2.  2   |            best-correctedvision, i.e. visual acuity obtained with
 76   II,     8.  2.  2   |     correction. Presenting vision, i.e. visual activity obtained
 77   II,     9           |   different age population groups (i.e. mothers at delivery, newborns,
 78   II,     9.  1.  1   |      proportion of infant deathsi.e. nearly three-quarters -
 79   II,     9.  1.  1   |           a mild clinical CP type, i.e. they walk without aids and
 80   II,     9.  1.  2   |     excluded from other subgroups (i.e. a child with an abdominal
 81   II,     9.  1.  2   |        folic acid supplementation (i.e. recommending that women
 82   II,     9.  2.  2   |       outside of the school system i.e. truants and those involved
 83   II,     9.  2.  3   |          functioning and abilityi.e. the International Classification
 84   II,     9.  3.  1   |           in early and middle age (i.e. testicular cancer characterized
 85   II,     9.  4.  3   |         with activity limitations (i.e. about 15 years for men and
 86   II,     9.  4.  3   |           women than in older men (i.e. individuals >70 years of
 87   II,     9.  4.  5   |     currently receive formal care, i.e. medical or social services.
 88   II,     9.  4.  5   |           that structural change - i.e. the creation of single agencies
 89   II,     9.  5.  4   |           the ‘chain of research’, i.e. hypothesis, diagnostic tools,
 90  III,    10.  2.  1   |          the recommended approach, i.e. a package of six policies
 91  III,    10.  2.  1   |            a number of countries, (i.e. as low as zero or 0.2g/l
 92  III,    10.  2.  1   |            16 year olds, lifetime (i.e. at least once in their life)
 93  III,    10.  2.  1   |           toothpaste has broughti.e. the reduced incidence and
 94  III,    10.  2.  1   |        modifiable risk behaviours, i.e. oral hygiene practices,
 95  III,    10.  2.  1   |            East European countries i.e. Lithuania (37%), Latvia (
 96  III,    10.  2.  1   |          effects are dose-related, i.e., toothpaste with a higher
 97  III,    10.  2.  1   |     imbalanced diet. Some of them (i.e. cardiovascular diseases,
 98  III,    10.  2.  1   |          needs) energy-dense food (i.e. food containing large amounts
 99  III,    10.  2.  1   |   collected with the same protocol i.e. a single 24-hour recall.
100  III,    10.  2.  1   |          to ensure that any claim, i.e.: nutritional, functional
101  III,    10.  2.  1   |            marketed 'in dose' form i.e. as pills, tablets, capsules,
102  III,    10.  2.  4   |       subgroups of the population (i.e., the identification of high,
103  III,    10.  2.  4   |     genomic-environmental pattern: i.e. although having the same
104  III,    10.  2.  4   |      individual genomic profiling: i.e., the concurrent detection
105  III,    10.  2.  4   |          between predictive tests (i.e., tests with 0-100% probability
106  III,    10.  2.  5   |      caregiver(s) (usually mother) i.e, attachment relation, is
107  III,    10.  2.  5   |          people only based on age (i.e. young old between 65 and
108  III,    10.  2.  5   |    intervention to promote health, i.e. health promoting interventions
109  III,    10.  4.  2   |        humans mainly through food (i.e. zoonoses) as a result of
110  III,    10.  4.  2   |        Parliament and the Council, i.e. EU Member States). It is
111  III,    10.  4.  2   |         so-called ALARA principle, i.e. as low as reasonably achievable,
112  III,    10.  4.  2   |     mechanism group” of compounds (i.e. compounds that show dose-addition)
113  III,    10.  4.  2   |         respect an absolute value (i.e. public health, consumer
114  III,    10.  4.  2   |          Margin of Exposure (MOE), i.e. the point selected on the
115  III,    10.  4.  3   |            with a major objective, i.e. to achieve a "good water
116  III,    10.  4.  3   |     Guidelines for drinking water, i.e. 10 μg/l (10 ppb).~ ~The
117  III,    10.  4.  4   |          and/or consumer services (i.e. tourism services, sports
118  III,    10.  4.  5   |          by aquatic or amphibious (i.e moving both on land and
119  III,    10.  4.  5   |           possible health effects (i.e. an increase of soft tissues
120  III,    10.  5.  2   |   demographic differences as well, i.e. account all analysis for
121  III,    10.  5.  3   |          because of CVD morbidity (i.e. 591 days per 1000 population)
122  III,    10.  5.  3   |            healthy worker effect’, i.e. that only people in good
123  III,    10.  6.  1   |       those ties. Social networks, i.e. social connectedness, make
124  III,    10.  6.  2   |          to be structural factors, i.e. conditions in society and
125   IV,    11.  1.  3   |     concept of avoidable mortality i.e. mortality which could have
126   IV,    11.  1.  4   |         care use and accessibility i.e. to what extent are there
127   IV,    11.  1.  5   |            by financial incentives i.e. no linear relationship between
128   IV,    11.  1.  6   |      combination of retrospective (i.e. fee-for-service) and prospective (
129   IV,    11.  1.  6   |  fee-for-service) and prospective (i.e. capitation, salaries) payment
130   IV,    11.  1.  6   |     prospective and may be ‘hard’ (i.e. penalties are incurred for
131   IV,    11.  1.  6   |           overspending) or ‘soft’ (i.e. overspending is not penalized).
132   IV,    11.  1.  6   |            than the reimbursement, i.e. it may encourage the ‘dumping’
133   IV,    11.  1.  6   |          made about outlier cases (i.e. treatment episodes with
134   IV,    11.  1.  6   |       higher administrative costs (i.e. Germany, Luxembourg, the
135   IV,    11.  2.  1   |            all kind of physicians, i.e. both general practitioners
136   IV,    11.  2.  1   |          and surgical specialties (i.e. curing illness and providing
137   IV,    11.  3.  2   |           public share of spending i.e. Austria, Belgium, Estonia,
138   IV,    11.  3.  2   |         pricing and reimbursement (i.e. the level of public subsidy).
139   IV,    11.  5.  5   |           at organizational level, i.e. institute a framework for
140   IV,    11.  6.  2   |          be expensive, regressive (i.e. benefits higher income earners
141   IV,    11.  6.  4   |          purchasers is capitation (i.e. the amount is determined
142   IV,    11.  6.  4   |         use of explicit regulation i.e. a benefits catalogue or
143   IV,    11.  6.  4   |    necessary to define indicators, i.e. measures that can be used
144   IV,    11.  6.  4   |           to define the benchmark (i.e. the pool of hospitals or
145   IV,    12.  2       |    timeframe as well as key tools (i.e. regulations and activity
146   IV,    12. 10       |     sexually transmitted diseases (i.e. Hepatitis B & C, HPV, Syphilis,
147   IV,    12. 10       |          the regional authorities (i.e. schools, municipalities)
148   IV,    13.  1       |         the root causes of health (i.e. health determinants) and
149   IV,    13.  2.  2   |            lower-income countries, i.e: estimated to be 2-6% of
150   IV,    13.  2.  3   |            highest disease burden, i.e. 9.5%. Estimations of environmental
151   IV,    13.  3       |           some 16% of EU citizens, i.e. 78 million people, are at
152   IV,    13.  3       |           some 16% of EU citizens, i.e. 78 million people, are at
153   IV,    13.  7.  5   |   interpretation of the Directive, i.e. the (im)possibilities for